2 September 2022
Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland
Swissmedic has temporarily authorised “Spikevax Bivalent Original/Omicron (mRNA-1273.214)” which is the first COVID-19 vaccine containing messenger ribonucleic acid (mRNA) against two coronavirus variants. Trials have shown that a booster dose with this bivalent vaccine produces a stronger immune response than a booster with Spikevax®, the original COVID-19 vaccine from Moderna against the Omicron variants BA.1 und BA.4/5. The side effects profile was similar to the second dose or the booster of the original vaccine, hence no new safety signals were found.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar